Abstract

Acute cerebrovascular diseases are a group of common clinical diseases characterized by abnormal cerebrovascular circulation. Among many common and frequently occurring diseases admitted to emergency and critical care departments, the mortality rate is high and the disability rate of surviving patients is also high. In addition to central injury in acute cerebrovascular diseases, which can lead to poor prognosis in patients, fluctuations in the properties and functions of local and circulating immune mediators can also trigger the body to enter an immune imbalance state, leading to poor prognosis in some patients after receiving systematic symptomatic support treatment. Betahistine hydrochloride is a histamine H1 receptor agonist that can resist platelet aggregation. The drug has a half-life of 5 h through liver metabolism and will not remain in the body, resulting in high safety. In addition, betahistine hydrochloride also has a diuretic effect, which can promote blood circulation, increase organ blood perfusion, reduce myocardial oxygen consumption, improve patient blood pressure levels and ultimately improve symptoms of cardiovascular and cerebrovascular ischemia and hypoxia. Therefore, this article mainly reviews the treatment of acute cerebrovascular disease with betahistine hydrochloride combined with atorvastatin, providing scientific reference for clinical treatment of acute cerebrovascular disease.